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ABSTRACT
Background: Classification of menopausal status is important for epidemiological and clini-
cal studies as well as for clinicians treating midlife women. Most epidemiological studies, in-
cluding the Study of Women’s Health Across the Nation (SWAN), classify women based on
self-reported bleeding history.
Methods: The Women’s Ischemia Syndrome Evaluation (WISE) study developed an algo-
rithm using menstrual and reproductive history and serum hormone levels to reproduce the
menopausal status classifications assigned by the WISE hormone committee. We applied that
algorithm to women participating in SWAN and examined characteristics of women with con-
cordant and discordant SWAN and WISE classifications.
Results: Of the 3215 SWAN women with complete information at baseline (1995–1997), 2466
(76.7%) received concordant classifications (kappa  0.52); at the fifth annual follow-up visit,
of the 1623 women with complete information, 1154 (72.7%) received concordant classifica-
tions (kappa  0.57). At each time point, we identified subgroups of women with discordant
SWAN and WISE classifications. These subgroups, ordered by chronological age, showed in-
creasing trends for menopausal symptoms and follicle-stimulating hormone (FSH) and a de-
creasing trend for estrogen (p  0.001).
Conclusions: The WISE algorithm is a useful tool for studies that have access to blood
samples for hormone data unrelated to menstrual cycle phase, with or without an intact
uterus, and no resources for adjudication. Future studies may want to combine aspects of
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the SWAN and WISE algorithms by adding hormonal measures to the series of bleeding
questions in order to determine more precisely where women are in the perimenopausal
continuum.
hormone committee. In this paper, we extend the
use of that algorithm by applying it to the cohort
of women participating in SWAN and examining
characteristics of women with concordant and
discordant SWAN and WISE menopausal status
classifications at various stages of the menopau-
sal transition. We consider the relative usefulness
of these two different types of menopausal status
classification algorithms—one that relies on self-
reports of menstrual bleeding and one that com-
bines bleeding data and hormone measure-
ments—for epidemiological and clinical studies.
MATERIALS AND METHODS
Study population
SWAN is a multicenter, multiethnic, longitu-
dinal, community-based study designed to char-
acterize the biological and psychosocial changes
that occur during the menopausal transition. The
SWAN cohort consists of 3302 women who were
age 42–52 years with at least one menstrual pe-
riod in the previous 3 months when they were re-
cruited into the SWAN study in 1995–1997. Wo-
men were recruited at seven study sites. The
population at each site included Caucasian wo-
men and women from one designated minority
(Boston, MA, Pittsburgh, PA, the Detroit, MI,
area, and Chicago, IL, recruited African Ameri-
can women; Newark, NJ, recruited Hispanic wo-
men; Oakland, CA, recruited Chinese women;
Los Angeles, CA, recruited Japanese women).
Women with previous hysterectomy or bilateral
oophorectomy were excluded from SWAN, as
were women who took oral contraceptives (OC)
or hormone therapy (HT) during the 3 months
before the screening interview. Women were seen
in the clinic at baseline and then annually for 5
years. The baseline and annual interviews in-
cluded bleeding history, medical history, and a
blood draw. For each follow-up visit, women
who reported a hysterectomy, bilateral oophorec-
tomy, or OC or HT use since their last visit were
excluded from analyses related to that visit. All
participants gave informed consent, and all study
procedures were reviewed and approved by the
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INTRODUCTION
CLASSIFICATION OF MENOPAUSAL STATUS is im-portant for epidemiological and clinical re-
search studies of midlife women, particularly for
studies of menopausal symptoms, aging, and the
role of reproductive hormones in various dis-
eases.1–5 Menopausal status classification is also
important to clinicians treating midlife women
who need to be able to identify perimenopausal
women in order to counsel them on ways to re-
duce their risk for chronic diseases, such as os-
teoporosis and heart disease, and to provide
treatment options for menopausal symptoms,
such as hot flashes and night sweats.6,7
Recently, considerable attention has been given
to the development of staging systems for repro-
ductive aging,8–11 but no single, agreed-upon
standard exists for classification of menopausal
status. Most epidemiological studies, including
the Study of Women’s Health Across the Nation
(SWAN), make their determination based on
questionnaire data about menstrual bleeding
changes.12,13 Clinicians, on the other hand, are
most likely to combine hormone measurements
with bleeding history to determine if a woman is
postmenopausal.14 Both of these approaches have
drawbacks, with the former approach being
likely to misclassify women who have irregular
cycles prior to the transition, and the latter hav-
ing unknown reliability as a result of the vari-
ability in hormone levels during the late peri-
menopause and postmenopause. A combination
of both bleeding questions and hormone levels is
intuitively appealing and has been proposed by
the Stages of Reproductive Aging Workshop
(STRAW) but is not frequently used, given the
difficulty in determining how to appropriately
categorize hormone levels in women who are un-
dergoing the menopausal transition and the in-
herent within-woman between-cycle variabil-
ity.6,15
The Women’s Ischemia Syndrome Evaluation
(WISE) study16,17 addressed this problem by de-
veloping an algorithm using menstrual and re-
productive history and results from serum hor-
mone assays to reproduce the menopausal status
classifications assigned by experts on the WISE
institutional review boards of the participating
institutions. A more detailed description of the
SWAN population has been published previ-
ously.18,19
WISE is a four-center study designed to im-
prove the diagnostic reliability of cardiovascular
testing in the evaluation of ischemic heart disease
in women.16 One of the major goals of the WISE
study is to evaluate the influence of cyclical hor-
mones, menopausal status, and blood reproduc-
tive hormone levels on cardiovascular physiol-
ogy, symptoms, and diagnostic testing results.
The population that served as the basis for the
WISE menopausal status algorithm consisted of
515 women, aged 21–86 years, undergoing clini-
cally ordered angiogram for suspected myocar-
dial ischemia. Women who were taking OC or
HT were excluded. The WISE study design called
for only one participant contact, and the blood
draw was not constrained to a specific time in the
menstrual cycle. The WISE hormone committee
reviewed and adjudicated menopausal status for
each of 186 women who could not be definitely
classified as postmenopausal, that is, previous bi-
lateral salpingo-oophorectomy (BSO) or age 55
years and no menses for 12 months. The WISE
study population and WISE hormonal menopau-
sal status algorithm have been previously de-
scribed.17
Measures of reproductive hormones
Phlebotomy was performed in the SWAN
study in the morning after overnight fast. Sub-
jects were scheduled for venipuncture on days
2–5 after the onset of menses whenever possible.
Women with blood draws that occurred outside
of days 2–5 were included in these analyses be-
cause the WISE algorithm allows for blood draws
at any time during the menstrual cycle.
All SWAN assays were performed on the ACS-
180 automated analyzer (Bayer Diagnostics Cor-
poration, Tarrytown, NY) at the CLASS labora-
tory at the University of Michigan using a
double-antibody chemiluminescent immunoas-
say with a solid-phase anti-IgG immunoglobulin
conjugated to paramagnetic particles, antiligand
antibody, and competitive ligand labeled with di-
methylacridinium ester (DMAE). The follicle-
stimulating hormone (FSH) assay is a modifica-
tion of a manual assay kit (Bayer Diagnostics)
using two monoclonal antibodies (mAb) directed
to different regions on the beta subunit, with a
lower limit of detection (LLD) of 1.05 mIU/mL.
The estradiol (E2) assay modifies the rabbit anti-
E2-6 ACS-180 immunoassay to increase sensitiv-
ity, with an LLD of 1.0 pg/mL. Duplicate E2 as-
says were conducted, with results reported as the
arithmetic mean for each subject, with a coeffi-
cient of variation (CV) of 3%–12%. FSH assays
were single determinations.20
The WISE study used the Diagnostic Products
Corporation (Los Angeles, CA) coat-a-count kits
for their FSH assay. E2 was measured using
steroid column extraction and subsequent assays.
The CLASS laboratory that performed the SWAN
FSH and E2 assays had previously determined
that differences in sample collection and storage,
as well as assay differences, caused systemati-
cally higher FSH readings in SWAN than in
WISE. Therefore, the CLASS laboratory recalcu-
lated the previously published WISE FSH cutoff
points of 10, 20, and 30 for menopausal classifi-
cation and converted them to SWAN FSH mea-
surements of 16, 33, and 50, respectively, in order
to account for differences in the two studies’ FSH
measurements (Dan McConnell, University of
Michigan, personal communication, 2004). The
CLASS laboratory determined that no adjust-
ments were necessary for the E2 cutoff points.
SWAN and WISE menopausal status algorithms
Following the Massachusetts Women’s Health
Study,13 SWAN defines four menopausal status
categories: premenopausal, 3 months of amen-
orrhea and no increase in menstrual irregularity
in the past year; early perimenopausal, 3
months of amenorrhea with some increase in
menstrual irregularity; late perimenopausal, be-
tween 3 and 11 months of amenorrhea; post-
menopausal, 12 or more consecutive months of
amenorrhea with no medical cause other than
menopause. SWAN classifies women who have
had a hysterectomy or a BSO as surgically meno-
pausal, a separate category from women who are
naturally postmenopausal.
The WISE hormonal classification committee,
consisting of two reproductive endocrinologists,
two clinical cardiologists, a statistician, and a
nurse, categorized each woman in the WISE
study into one of three status categories: pre-
menopausal, perimenopausal, or postmenopau-
sal.17 These classifications were based on age,
body mass index (BMI), smoking history, history
of a hysterectomy with or without bilateral or
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unilateral oophorectomy, cycle regularity, time
since last menstrual period (LMP), and serum
FSH, luteinizing hormone (LH), E2, estrone (E1),
and progesterone (PO) measurements. Using
these committee-defined menopausal status clas-
sifications as the reference standard, the commit-
tee iteratively simplified the classification process
into a decision tree by identifying the most im-
portant variables for status classification and es-
tablishing cutoff points that would reproduce the
experts’ status classification. The WISE algorithm
requires age, time since last menstrual period,
serum E2 and FSH values, and history of hys-
terectomy or BSO. Because SWAN separates sur-
gical menopause from all other menopausal
status classifications, we did not include the hys-
terectomy and BSO components of the WISE al-
gorithm in our classification comparisons. Figure
1 illustrates the WISE algorithm for women who
have not had a hysterectomy or BSO.
To evaluate agreement, we equated the SWAN
premenopausal and postmenopausal classifica-
tions to the WISE premenopausal and post-
menopausal classifications, respectively. Because
the WISE classification scheme includes a single
perimenopausal category and the SWAN classi-
fication scheme includes both early and late peri-
menopausal categories, we equated both the
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FIG. 1. WISE algorithm for women who have not had a hysterectomy or BSO.
SWAN early and SWAN late perimenopausal
classifications to the WISE perimenopausal clas-
sification.
We applied the two classification schemes to
the SWAN population at baseline and at the fifth
year of follow-up. Kappa statistics were com-
puted to assess agreement. Sensitivity and speci-
ficity were not computed because there is no 
single, agreed-upon standard for menopausal
classification. In order to examine differences be-
tween concordant and discordant women, we or-
dered the concordant and discordant subgroups
by mean chronological age, which we used as a
proxy for ovarian age. We then performed statis-
tical tests for trend to detect whether there were
linearly increasing or decreasing trends across the
groups for presence of menopausal symptoms in
the 2 weeks before the interview, for depressive
symptomatology, and for E2 and FSH levels. We
used the Cochrane-Armitage test for trend for di-
chotomous variable and an analogous nonpara-
metric test based on Cuzick’s Wilcoxon-type test
for trend21 for continuous variables (STATA
nptrend procedure). For follow-up visit 5, we lim-
ited this analysis to concordant and discordant
subgroups with 50 or more women.
RESULTS
Based on SWAN’s eligibility criteria, all wo-
men were classified as either premenopausal or
early perimenopausal by SWAN at baseline. We
applied the WISE hormonal algorithm to 3215
SWAN women (47% Caucasian, 29% African
American, 8% Chinese, 8% Hispanic, and 8%
Japanese) who had age, hormone measures, and
bleeding history information available at study
entry. Of these women, 1724 (53.6 %) were clas-
sified as premenopausal, and 1491 (46.4%) were
classified as early perimenopausal by the SWAN
status classification algorithm (Table 1). The ma-
jority of women (88.5%) who were classified as
premenopausal by SWAN were also classified as
premenopausal by WISE; 11.5% were classified as
WISE perimenopausal because they had an FSH
value 33. Of the women classified as early peri-
menopausal by SWAN, 63.0% were also classified
as perimenopausal by WISE, whereas 37% were
classified as premenopausal by WISE because of
irregular cycles and an FSH value 16. The 
majority of women (2466, 76.7%) received con-
cordant classifications with the SWAN and 
WISE algorithms based on information from the
SWAN baseline visit. The kappa statistic for
agreement was 0.52, indicating moderate agree-
ment.
To further explore discordance at baseline, we
categorized women into the following four cate-
gories and ordered the groups by mean chrono-
logical age:
1. Concordant for premenopausal
2. Discordant: SWAN early perimenopausal and
WISE premenopausal
3. Discordant: SWAN premenopausal and WISE
perimenopausal
4. Concordant for perimenopausal
Looking across these subgroups of women, we
found statistically significant linear trends
(Cochrane-Armitage test for trend) for increased
likelihood of reporting menopausal symptoms
(hot flashes, cold sweats, and night sweats) in the
2 weeks before the baseline interview as we
moved from the subgroups of women who were
earliest in the menopausal transition (concordant
for premenopausal) to those who were furthest
along in the transition (concordant for peri-
menopausal) (Table 2). As expected, we also
found significant linear trends for increasing
mean FSH levels and decreasing mean estrogen
levels as we moved from subgroups of women
who were earlier to those who were later in the
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TABLE 1. CROSS-TABULATION OF SWAN AND WISE MENOPAUSAL STATUS
CLASSIFICATIONS FOR 3215 SWAN WOMEN AT BASELINE
WISE WISE
Premenopausal Perimenopausal Total
SWAN premenopausal 1526 (47.5%) 198 (6.2%) 1724 (53.6%)
SWAN early 551 (17.1%) 940 (29.2%) 1491 (46.4%)
perimenopausal
Total 2077 (64.6%) 1138 (35.4%) 3215 (100%).
menopausal transition (STATA nptrend proce-
dure for continuous variables).
At the fifth follow-up interview, 1623 SWAN
women had complete information, had not had
a hysterectomy or BSO, and did not report HT
use since the last study visit. Table 3 shows the
cross-tabulation of SWAN and WISE menopau-
sal status classification at follow-up visit 5.
Thirty-five women (2.2%) who were identified
as Unable to classify by the WISE algorithm
were excluded from Table 3. Again, the major-
ity of women (1154, 72.7%) received concordant
classifications. The kappa statistic for agree-
ment was 0.57, again indicating moderate agree-
ment.
Because of the large number of possible dis-
cordant classifications, we limited our analysis of
concordant and discordant classification groups
at follow-up visit 5 to the six groups that con-
tained at least 50 women. The 80 women (5.0%)
with discordant classifications that did not fall
into one of these six groups were excluded from
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TABLE 2. BASELINE CHARACTERISTICS BY SWAN/WISE BASELINE CLASSIFICATIONSa
SWAN SWAN early SWAN SWAN early
premenopausal perimenopausal premenopausal perimenopausal
/WISE /WISE /WISE /WISE
premenopausal premenopausal perimenopausal perimenopausal p value
(n  1526) (n  551) (n  198) (n  940) for linear
% % % % trend
Menopausal symptoms—any in 2 weeks before baseine interview
Hot flashes 18 31 27 39 0.0001
Cold sweats 8 14 14 15 0.0001
Night sweats 23 34 32 37 0.0001
Feeling fearful 16 23 16 24 0.0001
Nervous 62 71 59 68 0.02
Heart racing 28 35 26 35 0.001
Frequent mood 46 59 42 56 0.0001
changes
Irritable 70 77 65 74 0.21
Depressed 21 31 22 26 0.01
(CES-D  16)
Median Median Median Median p value
(IQR)b (IQR) (IQR) (IQR) for trend
Age (years) 45.5 45.5 47.4 47.4 0.01
(43.7–47.5) (43.5–47.2) (45.0–49.3) (45.3–49.4)
Estrogen 60.8 68.1 26.9 42.7 0.01
(pg/mL) (39.3–90.3) (42.5–99.6) (18.8–42.6) (26.3–83.3)
FSH (mIU/mL) 13.5 11.1 46.5 28.2 0.01
(10.0–18.6) (8.5–13.2) (38.9–62.6) (19.6–48.9) 0.01
aDichotomous variables, p values from Cochrane-Armitage test for trend; continuous variables, p values from non-
parametric test for trend (STATA, nptrend procedure).
bIQR  interquartile range.
TABLE 3. CROSS-TABULATION OF SWAN AND WISE MENOPAUSAL STATUS
CLASSIFICATIONS FOR 1588 SWAN WOMEN AT FOLLOW-UP VISIT 5a
WISE WISE WISE
Premenopausal Perimenopausal Postmenopausal Total
SWAN premenopausal 87 (5.5%) 9 (0.6%) 0 (0.0%) 96 (6.0%)
SWAN early perimenopausal 336 (21.2%) 451 (28.4%) 0 (0.0%) 787 (49.6%)
SWAN late perimenopausal 17 (1.1%) 150 (9.4%) 53 (3.3%) 220 (13.9%)
SWAN postmenopausal 4 (0.3%) 15 (0.9%) 466 (29.3%) 485 (30.5%)
Total 444 (28.0%) 625 (39.4%) 519 (32.7%) 1588 (100%)
aWomen were excluded from analysis if they reported HT use since last study visit or had a hysterectomy or BSO.
this analysis. The groups were ordered by mean
chronological age:
1. Concordant for premenopausal
2. Discordant: SWAN early perimenopausal and
WISE premenopausal
3. Concordant: SWAN early perimenopausal and
WISE perimenopausal
4. Concordant: SWAN late perimenopausal and
WISE perimenopausal
5. Discordant: SWAN late perimenopausal and
WISE postmenopausal
6. Concordant for postmenopausal
Again, we found statistically significant linear
trends for increased likelihood of reporting
menopausal symptoms (hot flashes, cold sweats,
and night sweats) in the 2 weeks before the base-
line interview as we moved from subgroups of
women who were earlier in the menopausal tran-
sition to those who were later in the transition,
with a noticeable flattening out at the 60% level
for the reporting of hot flashes in the previous 2
weeks in the groups that were close to or had be-
come postmenopausal (Table 4). Again, as ex-
pected, we found significant linear trends for in-
creasing mean FSH levels and decreasing mean
estrogen levels as we moved from subgroups of
women who were earlier to those who were later
in the menopausal transition.
DISCUSSION
In this study, we applied the WISE menopau-
sal status classification algorithm, which includes
the use of hormone levels, to women who had
previously been classified using the SWAN
menopausal status classification algorithm,
which does not include hormone levels. We
found that the two algorithms agreed for 77% of
the SWAN women at baseline and for 73% of the
SWAN women at the fifth annual follow-up visit.
We further found that by combining the two al-
gorithms, we could categorize women more
finely. At baseline, we found highly significant
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TABLE 4. ANNUAL FOLLOW-UP VISIT 5 CHARACTERISTICS BY SWAN/WISE ANNUAL FOLLOW-UP VISIT 5
CLASSIFICATIONSa
SWAN SWAN early SWAN early SWAN late SWAN late SWAN
premenopausal perimenopausal perimenopausal perimenopausal perimenopausal postmenopausal
/WISE /WISE /WISE /WISE /WISE /WISE
premenopausal premenopausal perimenopausal perimenopausal postmenopausal postmenopausal p value
(n  87) (n  336) (n  451) (n  150) (n  53) (n  466) for linear
% % % % % % trend
Menopausal Symptoms—any in 2 weeks before annual follow-up visit 5 interview
Hot flashes 27 30 44 60 60 60 0.0001
Cold sweats 2 12 12 14 11 18 0.001
Night sweats 24 36 38 46 36 42 0.01
Feeling fearful 10 15 17 18 17 21 0.01
Nervous 55 68 64 58 64 59 0.07
Heart racing 25 28 24 26 23 28 0.67
Frequent mood 39 49 40 39 42 43 0.56
changes
Irritable 75 74 65 60 55 60 0.0001
Depressed 20 19 17 15 26 23 0.07
(CES-D  16)
Median Median Median Median Median Median p value
(IQR)b (IQR) (IQR) (IQR) (IQR) (IQR) for trend
Age (years) 49.1 49.3 50.3 51.2 53.2 53.6 0.01
(48.0–50.6) (48.2–50.8) (48.9–52.0) (49.3–53.0) (51.5–54.8) (51.8–55.2)
Estrogen 50.6 54.0 36.1 22.8 11.3 13.0 0.01
(pg/mL) (27.9–81.2) (31.2–109.2) (18.7–83.1) (14.1–45.2) (8.6–15.1) (9.4–18.7)
FSH (mIU/mL) 12.6 11.7 33.5 72.7 90.2 88.5 0.01
(9.6–18.7) (8.9–15.1) (21.1–57.8) (39.1–96.2) (74.8–116.4) (65.6–115.9)
aDichotomous variables, p values from Cochrane-Armitage test for trend; continuous variables, p values from non-
parametric test for trend (STATA, nptrend procedure).
bIQR  interquartile range.
differences in both estrogen and FSH levels be-
tween the two groups of women with discordant
classifications, suggesting that hormone mea-
surements may be useful when it is important to
determine where women are in the continuum
from premenopause to early perimenopause. At
follow-up visit 5, we found noticeable steady in-
creases in FSH values as we moved through the
various concordant and discordant classification
groups ordered according to mean chronological
age. Again, this suggests that hormone levels may
be useful for differentiating between premeno-
pause and early and late perimenopause.
Menopausal transition stage is important in
epidemiological and clinical research studies that
include midlife women and in studies focused on
understanding the natural history of the meno-
pausal transition or the effect hormonal and other
interventions have on that natural history. As the
menopausal transition is a gradual and variable
process, it is often difficult to determine a wo-
man’s menopausal status category. This study
compared two proposed algorithms for classifi-
cation and found moderate agreement between
them. With no single agreed-upon standard for
determining menopausal status, it is not surpris-
ing that two population-based algorithms that
include different number of stages show some
disagreement, particularly in regard to peri-
menopausal women.
The SWAN menstrually defined status cate-
gories are similar to those used by the Massa-
chusetts Women’s Health Study13 and included
in World Health Organization (WHO) reports.22
The WISE algorithm was developed using a clas-
sification tree approach, with validation against
classifications made by an expert committee. The
WISE algorithm can be applied to women who
may have stopped cycling for reasons unrelated
to the menopause transition, such as hysterec-
tomy, an important consideration for large epi-
demiological studies. Because SWAN’s menstru-
ally defined categories do not allow for
menopausal status classification for women who
have stopped cycling as a result of a hysterec-
tomy, these women were not included in the com-
parison of the two algorithms.
The best method for determining menopausal
status for a particular study or a particular wo-
man will depend on characteristics of the study
population or the individual, on the possibilities
for data collection, and on the purpose of the as-
sessment. For example, a study designed to test
guidelines for physicians’ counseling women on
when to start monitoring bone mineral density
(BMD) may need to depend on self-reported
bleeding. A cardiovascular clinical trial evaluat-
ing the vascular effects of exogenous hormones
may require precise measurements of endoge-
nous hormone levels irrespective of bleeding his-
tory. Finally, a patient with severe menopausal
symptomatology requiring treatment may war-
rant a combination of measurements of menstrual
history, prospective menstrual charting, and hor-
mone measurements to best assess her progress
through the transition, whereas a mildly symp-
tomatic patient will require a much less intensive
assessment.
Two important questions researchers must
consider are whether the additional information
provided by hormone assays will improve status
classification and whether the improvement is
sufficient to warrant the added participant bur-
den and cost. Although it has been shown that,
on average, FSH levels are higher in women who
are further along compared with those who are
earlier in the transition,15,23 FSH levels for an in-
dividual woman may be extremely variable in the
time leading up to the final menstrual period and,
therefore, cannot be used in isolation to deter-
mine menopausal status.24 Estrogen levels also
have been shown to be highly variable during the
menopausal transition.15,23
Although it is not recommended that hor-
mone levels alone be used to determine meno-
pausal status, the approach used by the WISE
algorithm combining hormone measurements
with age and bleeding history may be well
suited for study populations and clinical sam-
ples that include premenopausal and peri-
menopausal women who are not cycling regu-
larly because of various health conditions. The
WISE algorithm has the added benefit of cate-
gorizing women with a prior hysterectomy, a
group that constitutes approximately 30% of wo-
men in this age group in the United States.25 It
is not possible for the SWAN algorithm, which
is based on bleeding history, to assign meno-
pausal status to women who have undergone a
hysterectomy. On the other hand, the SWAN al-
gorithm has the advantage of differentiating be-
tween early and late perimenopause among wo-
men without hysterectomy.
Combining the two approaches may be use-
ful when there is a need to determine status
more precisely than is currently done by either
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SWAN or WISE. The STRAW proposed a stag-
ing system with seven stages ranging from 
early reproductive through late postmeno-
pause. STRAW participants considered men-
strual cyclicity, endocrinology, menopausal
symptoms, fertility, and pelvic anatomy when
developing their staging system for female re-
productive aging; however, STRAW’s staging
criteria depend primarily on changes in bleed-
ing characteristics and FSH levels.8 A recent
multicohort evaluation of the STRAW criteria
recommends inclusion of specific FSH values in
defining menopausal stage.26
The classification tree used in the WISE algo-
rithm was developed based on a small number
(n  32) of women considered perimenopausal
by the WISE hormone committee, all of whom
were undergoing clinically ordered angiograms
for suspected myocardial infarction.17 There-
fore, the decision points in the WISE algorithm
may not be generalizable to more diverse pop-
ulations.
Hormone levels may vary depending on the
specific laboratory and assay. In our study, it was
necessary to adjust the FSH, but not E2, levels be-
cause of differences in the SWAN and WISE FSH
assays.
CONCLUSIONS
The WISE algorithm is a useful tool for stud-
ies that have access to blood samples for hor-
mone data unrelated to menstrual cycle phase,
with or without an intact uterus, and no re-
sources for adjudication. Our findings suggest
that a menstrual status classification algorithm
that relies solely on bleeding data can effectively
distinguish among premenopausal, perimeno-
pausal, and postmenopausal women. Future
studies may want to combine aspects of the
SWAN and WISE algorithms by adding hor-
monal measures to the series of bleeding ques-
tions to determine more precisely, at a popula-
tion-based level, where women are in the
perimenopausal continuum. Clinicians with ac-
cess to more detailed information on their pa-
tients may be able to make more accurate as-
sessments of menopausal status for individual
women. Further work is needed to more pre-
cisely define the optimal bleeding and hormonal
criteria for staging menopausal aging, building
on these and other proposed approach.8–11
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NIH Program Office
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NIH Program Office
National Heart, Lung and Blood Institute: George Sopko and Patrice Desvigne-Nikkens, Program
Officers.
Data Coordinating Center
University of Pittsburgh, Pittsburgh, PA.
Clinical Coordinating Center and Reproductive Hormone Core Laboratory
Cedars-Sinai Medical Center, Los Angeles, CA.
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